Söndag 22 Mars | 19:11:40 Europe / Stockholm

Svenska | English

Argenx

Kalender

	Est. tid*
2027-03-03	N/A	Bokslutskommuniké 2026
2026-10-29	N/A	Kvartalsrapport 2026-Q3
2026-07-27	N/A	Kvartalsrapport 2026-Q2
2026-05-06	N/A	Årsstämma
2026-05-06	N/A	Kvartalsrapport 2026-Q1
2026-02-26	-	Bokslutskommuniké 2025
2025-11-18	-	Extra Bolagsstämma
2025-10-30	-	Kvartalsrapport 2025-Q3
2025-07-31	-	Kvartalsrapport 2025-Q2
2025-05-27	-	Årsstämma
2025-05-08	-	Kvartalsrapport 2025-Q1
2025-02-27	-	Bokslutskommuniké 2024
2024-10-31	-	Kvartalsrapport 2024-Q3
2024-07-25	-	Kvartalsrapport 2024-Q2
2024-05-09	-	Kvartalsrapport 2024-Q1
2024-05-07	-	Årsstämma
2024-03-21	-	Bokslutskommuniké 2023
2024-02-29	-	Bokslutskommuniké 2023
2023-10-31	-	Kvartalsrapport 2023-Q3
2023-07-27	-	Kvartalsrapport 2023-Q2
2023-05-04	-	Kvartalsrapport 2023-Q1
2023-05-02	-	Årsstämma
2023-03-02	-	Bokslutskommuniké 2022
2023-02-27	-	Extra Bolagsstämma
2022-10-27	-	Kvartalsrapport 2022-Q3
2022-09-08	-	Extra Bolagsstämma
2022-07-28	-	Kvartalsrapport 2022-Q2
2022-05-10	-	Årsstämma
2022-05-05	-	Kvartalsrapport 2022-Q1
2022-03-03	-	Bokslutskommuniké 2021
2021-10-28	-	Kvartalsrapport 2021-Q3
2021-07-29	-	Kvartalsrapport 2021-Q2
2021-05-14	-	Kvartalsrapport 2021-Q1
2021-03-31	-	Bokslutskommuniké 2020
2020-10-22	-	Kvartalsrapport 2020-Q3
2020-07-30	-	Kvartalsrapport 2020-Q2
2020-05-14	-	Kvartalsrapport 2020-Q1
2020-05-12	-	Årsstämma
2019-11-25	-	Extra Bolagsstämma

Beskrivning

Land	Nederländerna
Sektor	Hälsovård
Industri	Bioteknik

Argenx är verksamt inom bioteknik. Bolaget fokus finns inom utveckling av terapier för behandling av allvarliga autoimmuna sjukdomar och cancer. Bolagets ledande produktkandidat är till för att bland annat behandla myasthenia gravis, en autoimmun neuromuskulär sjukdom. Argenx har sina kunder runtom i Europa och har sitt huvudkontor i Zwijnaarde, Belgien.

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2026-03-20 21:01:00 argenx announces Annual General Meeting of Shareholders on May 6, 2026

2026-03-06 07:00:00 argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline 619,70 EUR | -2,19%

2026-02-26 07:00:00 argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update 658,70 EUR | -7,39%

2026-02-26 06:30:00 argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis 658,70 EUR | -7,39%

2026-02-23 07:00:00 argenx to Present at TD Cowen 46th Annual Healthcare Conference 702,10 EUR | -2,26%

2026-01-13 07:00:00 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG 691,10 EUR | +3,46%

2026-01-12 07:00:00 argenx Highlights 2026 Strategic Priorities 668,00 EUR | -3,58%

2026-01-06 07:00:00 argenx to Present at 44th Annual J.P. Morgan Healthcare Conference 687,10 EUR | +0,22%

2026-01-05 07:00:00 argenx Announces Leadership Transition Marking Next Evolution of Growth 685,60 EUR | -5,76%

2025-12-15 07:00:00 argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease 716,00 EUR | -5,37%

2025-11-18 22:01:00 argenx Announces Results of Extraordinary General Meeting of Shareholders 788,60 EUR | -0,87%

2025-10-30 07:00:00 argenx Reports Third Quarter 2025 Financial Results and Provides Business Update 693,20 EUR | -3,27%

2025-10-29 16:00:00 argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients 716,60 EUR | +0,06%

2025-10-23 07:00:00 argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025 706,10 EUR | -2,09%

2025-10-15 07:00:00 argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session 699,30 EUR | +1,64%

2025-10-03 22:01:00 argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

2025-08-28 07:00:00 argenx to Present at Upcoming Investor Conferences 600,60 EUR | -2,09%

2025-08-25 07:00:00 argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

2025-08-19 07:00:00 argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 564,20 EUR | -0,67%

2025-08-12 12:45:00 argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis 552,20 EUR | -2,01%

2025-07-31 07:00:00 argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update 598,70 EUR | +16,09%

2025-07-24 07:00:00 argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025 492,65 EUR | +0,47%

2025-06-30 07:00:00 argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes 471,65 EUR | -1,75%

2025-06-20 19:00:00 argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy 475,25 EUR | +1,17%

2025-06-11 00:01:00 argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease 507,05 EUR | -1,24%

2025-06-03 07:00:00 argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference 510,70 EUR | +1,47%

2025-05-28 22:01:00 argenx Announces Results of Annual General Meeting of Shareholders 512,05 EUR | -0,37%

2025-05-08 07:00:00 argenx Reports First Quarter 2025 Financial Results and Provides Business Update 484,65 EUR | -10,91%

2025-05-06 07:00:00 argenx to Present at BofA Securities 2025 Health Care Conference 568,40 EUR | -0,99%

2025-05-01 07:00:00 argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 559,70 EUR | 0,00%

2025-04-28 07:00:00 argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 541,40 EUR | +1,46%

2025-04-11 22:01:00 argenx Announces Annual General Meeting of Shareholders on May 27, 2025 504,65 EUR | +1,07%

2025-04-10 23:47:43 argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy 504,65 EUR | +1,07%

2025-04-08 07:00:00 argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP 517,55 EUR | +4,05%

2025-03-07 07:00:00 argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting 555,50 EUR | -4,57%

2025-02-27 07:00:00 argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update 615,70 EUR | +3,06%

2025-02-25 07:00:00 argenx to Present at TD Cowen 45th Annual Healthcare Conference 608,00 EUR | -0,69%

2025-02-20 07:00:00 argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 608,60 EUR | -0,62%

2025-01-13 07:00:00 argenx Highlights 2025 Strategic Priorities 638,50 EUR | -1,30%

2025-01-06 07:00:00 argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference 607,30 EUR | +0,35%

2024-12-27 07:00:00 argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy 601,20 EUR | +0,74%

2024-11-26 07:00:00 argenx to Present at Upcoming Investor Conferences 584,00 EUR | +1,07%

2024-11-20 07:00:00 argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies 565,20 EUR | +5,29%

2024-11-11 13:30:00 argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China 558,30 EUR | +1,62%

2024-11-05 07:00:00 argenx to Participate at Upcoming Investor Conferences 540,60 EUR | -0,28%

2024-10-31 07:00:00 argenx Reports Third Quarter 2024 Financial Results and Provides Business Update 539,70 EUR | +5,04%

2024-10-24 07:00:00 argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 511,70 EUR | -2,21%

2024-10-15 07:00:00 argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions 503,85 EUR | +0,95%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Argenx

Kalender

Beskrivning

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden